News

Eli Lilly and Biogen/Eisai’s extension trials make waves in Alzheimer’s market

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...
BioSpace3d

Biogen, Eisai’s Leqembi Slows Alzheimer’s Progression Through 4 Years of Treatment

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...
Precision Medicine Online1d

Eli Lilly, Eisai Share Data on Differing Treatment Duration Strategies for Pricey Alzheimer's Drugs

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...
BioSpace2d

Biogen’s Leqembi Push Getting Easier as CEO Eyes Early-Stage Pipeline Restock

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...
Seeking Alpha2mon

Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal ...

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...
Morningstar2mon

Eisai projects Leqembi® revenue to total JPY 76.5 ... - Morningstar

Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026) Provided by PR Newswire May 15, 2025, 1:56:00 AM ...
KTLA2mon

Eisai projects Leqembi® revenue to total JPY 76.5 billion for ... - KTLA

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...